Kathleen M Dungan MD

Diabetes, Lipid Metabolism

Professor of Medicine, Ohio State University

543 Taylor Ave2nd FloorColumbus, OH 43203
Phone+1 614-685-3333
Fax+1 614-366-0345

Dr. Dungan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dungan's full profile Already have an account?

Summary

Dr. Kathleen Dungan is an endocrinologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute, and Chillicothe Veterans Affairs Medical Center. She received her medical degree from Ohio State University College of Medicine and has been in practice 16 years. She specializes in diabetes and lipid metabolism.

Education & Training

University of North Carolina HospitalsFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006
University of North Carolina HospitalsResidency, Internal Medicine, 2001 - 2004
Ohio State University College of MedicineClass of 2001

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2006 - 2027
NC State Medical License 2001 - 2006
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir
COMPLETED
PHASE4
Intensive Glycemic Control for Congestive Heart Failure Exacerbation
COMPLETED
PHASE2
Glycemic Control and Variability for Congestive Heart Failure Exacerbation
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis.
Yijie Cheng, Joshua W Gaborcik, Rachel M Smith, Kathleen Dungan, Andrew C Stone
The Annals of Pharmacotherapy. 2026-07-08
Benefits and Barriers to Use of Continuous Glucose Monitoring 24 Weeks Following Hospital Discharge.
Melanie Natasha Rayan, Cecilia Wallace, Sara Folk, Cara Harris, Eileen Faulds
Endocrine Practice. 2026-07-01
5 citations
Continuous Glucose Monitoring in the Intensive Care Unit: A Multicenter, Retrospective Hospital-Based Analysis.
Eileen R Faulds, Joi C Hester, Yasaman Badakhshi, Joshua D Miller, Rosalind C Basil
Journal of Diabetes Science and Technology. 2026-07-01

Lectures

Remote Monitoring for Diabetes: Embracing Technology to Improve Patient Care
5/25/2022
A Comparison of Continuous Intravenous Insulin and Subcutaneous Insulin among Patients with Type 2 Diabetes and Congestive Heart Failure Exacerbation
Columbus, OH - 6/16/2014

Authored Content

Capsule 65 - Maintaining Muscle Mass While Taking GLP-1sMarch 2026
Podcast 64 - Is Metformin Still the First-Line Treatment for Type 2 Diabetes?January 2026
Capsule 59 - Simplified Prescription of Diabetes Technology and MedicationsSeptember 2025

Press Mentions

GLP-1 Drug Shortages: How Do They Affect Patients with Diabetes?November 8th, 2024
Ozempic and Wegovy May Aid Anti-Cancer ‘Natural Killer’ CellsMay 16th, 2023
Diabetes Drugs May Help Reduce Risk of Cardiovascular Events in Older AdultsMay 8th, 2023

Grant Support

Epidemiology and Pathophysiology of Acute Pancreatitis-related Diabetes MellitusOHIO STATE UNIVERSITY2020–2030
Intensive Glycemic Control For Congestive Heart Failure ExacerbationNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
Glycemic Control And Variability In Congestive Heart Failure ExacerbationNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2009